Following the 18th European Hematology Association Congress, pharmaphorum's Hannah Blake spoke with hematology expert, Dr Moshe Talpaz, to find out more about the research and development landscape of ...

Updated Positive Data at ASH 2025 Reinforce the Potential of Incyte's INCA033989, its First-in-Class mutCALR-Targeted ...

Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF ...

Incyte INCY announced that the FDA has granted the Breakthrough Therapy designation to its investigational, first-in-class, ...

For years, the search for a stem cell donor has felt like a quest for a rare key-one that fits a lock with eight intricate tumblers, each representing a genetic marker.

Overall survival was twice as long for people treated with Columvi in combination with GemOx versus MabThera/Rituxan plus ...

For years, the search for a stem cell donor has felt like a quest for a rare key—one that fits a lock with eight intricate tumblers, each representing a genetic marker. For many patients with blood ...

Long-term follow-up of EPYSQLI's Phase 3 study showed consistency of safety data between the initial 52-week period and the extended treatment period up to 158 weeks No new safety signals or fatal ...

First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in ...

Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF) Induction of ...